Gelareh Abedi

University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States

Are you Gelareh Abedi?

Claim your profile

Publications (6)10.76 Total impact

  • Gelareh Abedi, Ron A Adelman, Sarwat Salim
    [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Purpose: To review recent literature regarding ocular hypertension following intravitreal antivascular endothelial growth factors (anti-VEGF). Method: An electronic literature search was performed using MEDLINE, OVID, and PubMed. Key search terms were elevated IOP, anti-VEGF, sustained IOP elevation in anti-VEGF, chronic intraocular pressure elevation in anti-VEGF, high IOP with anti-VEGF, acute elevation in intraocular pressure with anti-VEGF, glaucoma and anti-VEGF. Result: Transient elevation of intraocular pressure after intravitreal anti-VEGF injection is due to temporary increase in volume, and the acute spike generally does not affect a healthy eye. Caution should be taken in a glaucomatous eye, and pretreatment with an IOP-lowering medication is recommended. Persistent elevation of intraocular pressure is more common than previously thought and may be correlated to several factors including increased number of intravitreal injections. Conclusion: Persistent ocular hypertension may be associated with intravitreal anti-VEGF injections. Physicians should be aware of this condition and monitor their patients for persistent ocular hypertension, especially in eyes with preexisting glaucoma. Prompt diagnosis and treatment can prevent potential loss of vision.
    Seminars in ophthalmology 04/2013; · 1.09 Impact Factor
  • Albrecht von Graæes Archiv für Ophthalmologie 01/2012; · 1.93 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of this paper is to study the differences between central subfield macular thickness (CSMT) measurements obtained by time-domain Stratus optical coherence tomography (OCT) and Cirrus spectral domain OCT (Carl Zeiss Meditec, Dublin, CA) and to formulate an equation to convert CSMT values from one to the other. CSMT were measured by both Stratus Macula OCT and Cirrus Macula OCT in 46 healthy subjects. Agreement between measurements was calculated using Lin's concordance coefficient. The average age of our group was 30 with the logMAR visual acuity of -0.015. The Stratus CSMT measurement (mean ± standard deviation) 193.91 ± 21.7 was statistically significant from the Cirrus CSMT measurement 252.82 ± 28.4 (p < 0.001). The transformation equation 0.76×-0.51 from Cirrus to Stratus resulted in values that best agreed with the observed Stratus OCT values. We identified a significant difference of CSMT measurements between Stratus and Cirrus. The Cirrus typically gave a higher value of CSMT. We derived a linear equation to convert the measurements from Cirrus to Stratus which resulted in transformed values that concord with the observed Stratus OCT values.
    Albrecht von Graæes Archiv für Ophthalmologie 07/2011; 249(9):1353-7. · 1.93 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: To describe a case of successful treatment of acute retinal necrosis with a combination of antivirals and intravenous immunoglobulin. Methods: This is a case report of a 77-year-old white man diagnosed with unilateral acute retinal necrosis. Results: Combination therapy with systemic antivirals, prophylactic laser retinopexy, and intravenous immunoglobulin halted progression of retinitis and preserved visual acuity. Conclusion: Acute retinal necrosis is an aggressive disease with significant risk of vision loss even when treated with appropriate therapy. In this report, the authors describe a case of successful treatment with a combination of systemic antivirals and intravenous immunoglobulin. Intraocular antiviral injection plus systemic treatment remain to be a more cost-effective option.
    Retinal Cases & Brief Reports 12/2010; 5(4):363-365.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To report 1-year visual and anatomic outcomes of a prospective, double-masked randomised clinical trial comparing bevacizumab with ranibizumab for the treatment of age-related macular degeneration (AMD). Patients who met inclusion criteria were randomised 2 : 1 to bevacizumab or ranibizumab. All subjects and investigators (except for the pharmacist responsible for study assignments) were masked to treatment arms. Visual acuity was taken on Early Treatment Diabetic Retinopathy Study chart. Patients were given either bevacizumab or ranibizumab every month for the first 3 months, followed by an optical coherence tomography-guided, variable-dosing treatment schedule. Main outcomes measured included visual acuity, foveal thickness, and total number of injections over the 1-year treatment period. In total, 15 patients received bevacizumab and 7 patients received ranibizumab. The average pre-operative visual acuity was 34.9 letters in the bevacizumab group, and 32.7 letters in the ranibizumab group. At 1-year follow-up, mean vision was 42.5 letters in the bevacizumab group, and 39.0 letters in the ranibizumab group. Two-tailed t-test failed to showed statistical significance between the two groups (P=0.5). Patients in the bevacizumab group underwent an average of eight injections, whereas patients in the ranibizumab group underwent a mean of four injections (P=0.001). The 1-year outcomes of a prospective, double-masked, randomised clinical trial comparing bevacizumab with ranibizumab failed to show a difference in visual and anatomic outcomes between the two treatments for choroidal neovascularisation in AMD. Total injections given over the treatment period were significantly different between the two groups. Further studies with larger sample sizes are warranted.
    Eye (London, England) 10/2010; 24(11):1708-15. · 1.97 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To report early outcomes of a prospective, double-masked, controlled trial comparing bevacizumab (Avastin; Genentech Inc, South San Francisco, California, USA) to ranibizumab (Lucentis; Genentech Inc) for the treatment of age-related macular degeneration. Prospective, double-masked, randomized clinical trial. This is a single-center, randomized clinical trial at the Boston Veterans Affairs Healthcare System. Patients who met inclusion criteria were randomized 2:1 to bevacizumab or ranibizumab. Each patient contributed 1 eye to the study. All subjects and investigators (except for the pharmacist responsible for study assignments) were masked to treatment arms. Visual acuity (VA) was checked on Early Treatment Diabetic Retinopathy Study (ETDRS) chart. Patients were given either bevacizumab or ranibizumab every month for the first 3 months, followed by optical coherence tomography-guided, variable-dosing schedule. Main outcomes measured were VA and foveal thickness. Twenty patients completed the 6-month follow up. Thirteen patients received bevacizumab and 7 patients received ranibizumab. No subjects in either group lost more than 15 letters on ETDRS chart. The average preoperative VA was 31.6 letters in the bevacizumab group and 30.4 letters in the ranibizumab group. At 6 months follow-up, mean vision was 46.4 letters in the bevacizumab group and 37.4 letters in the ranibizumab group. Two-tailed ttest failed to show statistical significance between the two groups. Patients in the bevacizumab group underwent an average of 5 injections, while patients in the ranibizumab group underwent a mean of 4 injections. Early results of a head-to-head, randomized, double-masked, prospective, single-center controlled trial between bevacizumab and ranibizumab show no difference in efficacy between the two treatments for choroidal neovascularizaton in the treatment of age-related macular degeneration. As this study conveys results of a small number of patients, further studies with larger sample sizes are needed in order to establish statistical significance.
    American journal of ophthalmology 10/2009; 148(6):875-82.e1. · 3.83 Impact Factor